Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Cancer Sci. 2023 Sep;114(9):3783-3792. doi: 10.1111/cas.15853. Epub 2023 Jun 19.
Pancreatic ductal adenocarcinoma (PDAC) is physically palpated as a hard tumor with an unfavorable prognosis. Assessing physical features and their association with pathological features could help to elucidate the mechanism of physical abnormalities in cancer tissues. A total of 93 patients who underwent radical surgery for pancreatic and bile duct cancers at a single center hospital during a 28-month period were recruited for this study that aimed to estimate the stiffness of PDAC tissues compared to the other neoplasms and assess relationships between tumor stiffness and pathological features. Physical alterations and pathological features of PDAC, with or without preoperative therapy, were analyzed. The immunological tumor microenvironment was evaluated using multiplexed fluorescent immunohistochemistry. The stiffness of PDAC correlated with the ratio of Azan-Mallory staining, α-smooth muscle actin, and collagen I-positive areas of the tumors. Densities of CD8 T cells and CD204 macrophages were associated with tumor stiffness in cases without preoperative therapy. Pancreatic ductal adenocarcinoma treated with preoperative therapy was softer than that without, and the association between tumor stiffness and immune cell infiltration was not shown after preoperative therapy. We observed the relationship between tumor stiffness and immunological features in human PDAC for the first time. Immune cell densities in the tumor center were smaller in hard tumors than in soft tumors without preoperative therapies. Preoperative therapy could alter physical and immunological aspects, warranting further study. Understanding of the correlations between physical and immunological aspects could lead to the development of new therapies.
胰腺导管腺癌(PDAC)在临床上表现为质地坚硬的肿瘤,预后不良。评估其质地特征及其与病理特征的相关性,有助于阐明癌症组织质地异常的机制。本研究共纳入了 93 例在单中心医院接受胰腺和胆管癌根治性手术的患者,旨在评估 PDAC 组织与其他肿瘤相比的硬度,并评估肿瘤硬度与病理特征之间的关系。分析了 PDAC 的质地改变和病理特征,包括术前治疗和无术前治疗的情况。使用多重荧光免疫组化评估肿瘤的免疫微环境。PDAC 的硬度与 Azan-Mallory 染色、α-平滑肌肌动蛋白和胶原 I 阳性肿瘤区域的比例相关。在无术前治疗的情况下,CD8 T 细胞和 CD204 巨噬细胞的密度与肿瘤硬度相关。接受术前治疗的 PDAC 比未接受治疗的更软,且术前治疗后,肿瘤硬度与免疫细胞浸润之间的关联不再明显。我们首次观察到人类 PDAC 中肿瘤硬度与免疫特征之间的关系。在无术前治疗的情况下,硬肿瘤的肿瘤中心免疫细胞密度小于软肿瘤。术前治疗可能会改变肿瘤的质地和免疫方面,需要进一步研究。了解物理和免疫方面的相关性可能会导致新疗法的开发。